Ovarian Cancer Recurrent

Oncology·MeSH: Ovarian Neoplasms

Prevalence

24.0 / 100K

Incidence

10.6 / 100K/yr

7 drugs in development·3 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
Datopotamab Deruxtecan	Merck & Co., Inc. (MRK)

Phase 2(1)

Drug	Company
Raludotatug Deruxtecan	Merck & Co., Inc. (MRK)

Phase 1(2)

Drug	Company
Rintatolimod	Merck & Co., Inc. (MRK)
Rintatolimod	Merus N.V. (MRUS)

Phase 1/Phase 2(1)

Drug	Company
Temozolomide capsule	UNITED THERAPEUTICS Corp (UTHR)

Phase 4(2)

Drug	Company
AL	UNITED THERAPEUTICS Corp (UTHR)
Niraparib oral capsule	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 7 drugs in development for Ovarian Cancer Recurrent across 3 companies.

There are 4 clinical trials targeting Ovarian Cancer Recurrent tracked by BioSniper.

The estimated prevalence of Ovarian Cancer Recurrent is approximately 24.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.